Lo studio presentato al congresso sin bologna 2019
Kuzik® was well tolerated: in a numerical scale from 1 to 10 the average score was 9,5 ( range 8 -10) ; the compliance of patients was optimal, no side effect related to product were reported and no weight gain in patients occurred. A clear improvement of the patient’s asthenia should be noted. Regarding efficacy, at the end of treatment , in total population all parameters analyzed were significantly improved.
Our study clearly demonstrated the benefits, safety, and good tolerability of Kuzik® in the prophylaxis of migraine, with and without aura